Zobrazeno 1 - 10
of 236
pro vyhledávání: '"Yasutoshi, Kuboki"'
Autor:
Yasutoshi Kuboki, Masafumi Ikeda, Shigehisa Kitano, Takafumi Koyama, Noboru Yamamoto, Yuki Yamaguchi, Yuki Nakagawa, Takaaki Ishida, Hidenori Mizugaki, Takatsugu Narikiyo, Ryoko Takubo, Chika Ogami, Mayuko Sekiya
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Immunosuppressive conditions within the tumor microenvironment (TME) can allow tumors to evade the immune system, including by hampering programmed death ligand 1 (PD-L1) inhibitor activity. Interleukin (IL)-8 contributes to immunosuppress
Externí odkaz:
https://doaj.org/article/3d04b9ef93094c8580ba143d1ba1c0ee
Autor:
Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu
Publikováno v:
Cancer Medicine, Vol 13, Iss 8, Pp n/a-n/a (2024)
Abstract Background Retifanlimab is a humanized monoclonal antibody targeting programmed death protein‐1, and INCB001158 is an oral arginase inhibitor. This phase Ib study investigated retifanlimab, INCB001158, and their combination in Japanese pat
Externí odkaz:
https://doaj.org/article/054b73aa0e9c4d059dd35a08e6fa57cd
Autor:
Naoya Sakamoto, Saori Mishima, Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Takayuki Yoshino, Takeshi Kuwata, Kohei Shitara, Yoshiaki Nakamura, Daisuke Kotani, Masashi Wakabayashi, Shohei Koyama, Hiroyoshi Nishikawa, Yosuke Tanaka, Shogo Takei, Itaru Endo, Motohiro Kojima, Toshihide Ueno, Hiroyuki Mano, Shota Fukuoka, Yi-Tzu Lin, Hiroki Hara, Shinya Kojima
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background Immune checkpoint inhibitor (ICI) combinations represent an emerging treatment strategies in cancer. However, their efficacy in microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal cancer (CRC) is variable. Here, a m
Externí odkaz:
https://doaj.org/article/2be9529f9843474fb27cb25f1bcfd88c
Autor:
Dae Ho Lee, Hye Ryun Kim, Bhumsuk Keam, Ken Kato, Yasutoshi Kuboki, Haiyan Gao, Alejandro Yovine, Scott H. Robbins, Myung‐Ju Ahn
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 16066-16075 (2023)
Abstract Background Advanced or metastatic esophageal squamous cell carcinoma (ESCC) is associated with poor prognosis; new first‐line systemic treatment options are needed. Combining immuno‐oncology therapies with standard chemotherapy may repre
Externí odkaz:
https://doaj.org/article/3fc7742bfbf64ff8a02140d2ee8764c4
Autor:
Yutaka Fujiwara, Yasutoshi Kuboki, Masayuki Furukawa, Nobumasa Mizuno, Hiroki Hara, Tatsuya Ioka, Makoto Ueno, Yasuo Takahashi, Shunji Takahashi, Shinji Takeuchi, Christine Lihou, Tao Ji, Chenwei Tian, Toshio Shimizu
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10597-10611 (2023)
Abstract Background FIGHT‐102 was a phase 1, dose‐escalation, dose‐expansion study of pemigatinib in Japanese patients with advanced solid tumors. Here, we report safety, tolerability, and preliminary efficacy of pemigatinib from FIGHT‐102. M
Externí odkaz:
https://doaj.org/article/9baedb4c4d12487081450e5da764609a
Autor:
Yasutoshi Kuboki, Takako Eguchi Nakajima, Takafumi Koyama, Eriko Sumi, Kotaro Suzuki, Agnish Dey, Hideaki Kagehara, Petar Pop-Damkov, Eiki Maeda, Takenori Akaike, Kondala Atkuri, Masashi Ochi, Ganesh M Mugundu, Aman Singh
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2a19b131d9514d939273cfdd5ff527fa
Autor:
Takayuki Yoshino, Julien Taieb, Yasutoshi Kuboki, Per Pfeiffer, Amit Kumar, Howard S. Hochster
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Trifluridine/tipiracil plus bevacizumab (FTD/TPI + BEV) has shown efficacy and tolerability in refractory metastatic colorectal cancer (mCRC). Because randomized controlled trial (RCT) data comparing FTD/TPI + BEV with FTD/TPI are lacking
Externí odkaz:
https://doaj.org/article/96c8a39f041a48ffb9a10c68d06ec9e4
Autor:
Yasutoshi Kuboki, Tomohiro Nishina, Tomoko Fujita, Naoto Yoshizuka, Ko Sugibayashi, Kosho Murayama
Publikováno v:
BMJ Open, Vol 12, Iss 10 (2022)
Objectives We assessed the safety, tolerability, pharmacokinetics, preliminary antitumour activity and pharmacodynamics of danvatirsen, an antisense oligonucleotide targeting signal transducer and activator of transcription 3 (STAT3), monotherapy and
Externí odkaz:
https://doaj.org/article/e89310aca50c4a42a540ff444ccd9e81
Autor:
Daisuke Kotani, Yasutoshi Kuboki, Satoshi Horasawa, Asumi Kaneko, Yoshiaki Nakamura, Akihito Kawazoe, Hideaki Bando, Hiroya Taniguchi, Kohei Shitara, Takashi Kojima, Akihito Tsuji, Takayuki Yoshino
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. This retro
Externí odkaz:
https://doaj.org/article/5353642cd7e043c7a448adae57648b7d
Autor:
Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Daisuke Kotani, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Takeshi Kuwata, Akihito Tsuji, Kohei Shitara
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood. Methods Patients (pts) with AGC who were treated with nivolumab after two or more chemotherapy regime
Externí odkaz:
https://doaj.org/article/6bb077a4afc0401982a619dd6d4c130c